Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$972.52M+453.71%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brandon K. Sim
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Employees
- 3,000
- Beta
- 0.91
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 2.80
Financials
Revenue
$972.52M+453.7%Net Income
$19.74M+55.9%EBITDA
$43.21M-52.3%Free Cash Flow
$92.93M+560.5%EPS (diluted)
$0.40+42.9%Shares Outstanding (diluted)
49.78M+8.6%Operating Expenses
$54.15MCash & Debt
$400.79MReturn of Capital
$4.56MRevenue by Segment (annual)
$3.18BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.18B | $22.49M | $0.46 |
| 2024 | $2.03B | $43.15M | $0.91 |
| 2023 | $1.39B | $60.72M | $1.30 |
| 2022 | $1.14B | $45.17M | $1.00 |
| 2021 | $773.91M | $68.92M | $1.57 |
| 2020 | $370.25M | $-23.75M | $1.04 |
| 2019 | $560.62M | $14.12M | $0.41 |
| 2018 | $519.91M | $10.84M | $0.33 |
| 2017 | $357.75M | $25.80M | $1.01 |
| 2015 | $44.05M | $-9.34M | $0.00 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.67
- Implied price
- $36.36
- Return from $35.88
- 0.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $18.08 — -49.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 38 | 46 | 54 | 62 | 70 |
|---|---|---|---|---|---|
| -2.0% | -15.2% | -11.9% | -9.0% | -6.5% | -4.2% |
| 3.0% | -10.9% | -7.4% | -4.4% | -1.7% | 0.7% |
| 8.0% | -6.5% | -2.9% | 0.3% | 3.1% | 5.6% |
| 13.0% | -2.2% | 1.6% | 4.9% | 7.8% | 10.5% |
| 18.0% | 2.1% | 6.1% | 9.5% | 12.6% | 15.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-58.33%Social Signal Score
Mentions (4)
- Newsbusinesswire.com·7d ago·Negative
ASTH Investors Have Opportunity to Join Astrana Health, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $ASTH--ASTH Investors Have Opportunity to Join Astrana Health, Inc. Fraud Investigation with SBS Law.
View source ↗ - Newsbusinesswire.com·10d ago·Negative
PRIVACY ALERT: AWKO Law Investigating Astrana Health Data Breach SAN FRANCISCO--(BUSINESS WIRE)--AWKO Law LLP is investigating a data breach that led to unauthorized access to the sensitive information of individuals affiliated with Astrana Health, Inc.'s subsidiary, Astrana Health Management, Inc. Astrana Health, Inc. is a California-based technology-powered healthcare company that operates as a Management Services Organization (MSO). On September 23, 2026, Astrana Health, Inc. disclosed to the
View source ↗ - Newsglobenewswire.com·13d ago·Neutral
Lowey Dannenberg, P.C. is Investigating Astrana Health, Inc. (NASDAQ: ASTH) for Potential Violations of the Federal Securities Laws NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C.
View source ↗ - Newsseekingalpha.com·54d ago·Positive
Astrana Health: 81% Full-Risk And Profitable Astrana Health is rated a buy, trading at a 46% discount to peers despite sector-wide reserve releases clarifying earnings quality concerns. ASTH's Care Enablement platform drove G&A costs from 7.75% to 5.57% of revenue, quadrupling third-party revenue year-over-year and supporting durable profit at scale. Organic growth is driven by a mix-shift into full-risk capitation, with management projecting ongoing revenue-per-member expansion and a robust con
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $0.44 per share
Typical surprise -39.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.40 vs $0.34beat
- Thu, May 7$0.30 vs $0.29beat
- Mon, Mar 2$0.12 vs $0.15miss
- Thu, Nov 6$0.01 vs $0.47miss
- Thu, Aug 7$0.19 vs $0.36miss
- Thu, May 8$0.14 vs $0.23miss
Estimates and results for ASTH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ASTH officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ASTH.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.